Huan Meng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Huan Meng has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Hua-Min Zhang
Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning, 116001, China
2 shared publications - Jia-Chen Xue
Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning, 116001, China
2 shared publications - Qinggao Zhang
Immunology Biology Key Laboratory, Yanbian University, Yanji, Jilin 133002, P.R. China
2 shared publications - Shuo Yuan
Chronic Diseases Research Center, Dalian University College of Medicine, Dalian, Liaoning, China
2 shared publications - Xiao-Ting Hou
Chronic diseases research center, Dalian University College of Medicine, Dalian, Liaoning, 116622, China
2 shared publications - Bao-Hong Liu
Chronic diseases research center, Dalian University College of Medicine, Dalian, Liaoning, 116622, China
1 shared publication
Latest Publications
- Open Access
- 1 May 2025
- Published by Elsevier in Phytomedicine
- Vol. 143, 156640
Polyphyllin Ⅵ modulates macrophage polarization through autophagy-NLRP3 inflammasome to alleviate inflammatory bowel disease
- 1 May 2025
- Published by Elsevier in Phytomedicine
- Vol. 143, 156640
Open AccessPolyphyllin Ⅵ modulates macrophage polarization through autophagy-NLRP3 inflammasome to alleviate inflammatory bowel disease
- Open Access
- 31 July 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (15) , 8494
Stem Cell-Based Therapies for Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) is a chronic, relapsing disease that severely affects patients’ quality of life. The exact cause of IBD is uncertain, but current studies suggest that abnormal activation of the immune system, genetic susceptibility, and altered intestinal flora due to mucosal barrier defects may play an essential role in the pathogenesis of IBD. Unfortunately, IBD is currently difficult to be wholly cured. Thus, more treatment options are needed for different patients. Stem cell therapy, mainly including hematopoietic stem cell therapy and mesenchymal stem cell therapy, has shown the potential to improve the clinical disease activity of patients when conventional treatments are not effective. Stem cell therapy, an emerging therapy for IBD, can alleviate mucosal inflammation through mechanisms such as immunomodulation and colonization repair. Clinical studies have confirmed the effectiveness of stem cell transplantation in refractory IBD and the ability to maintain long-term remission in some patients. However, stem cell therapy is still in the research stage, and its safety and long-term efficacy remain to be further evaluated. This article reviews the upcoming stem cell transplantation methods for clinical application and the results of ongoing clinical trials to provide ideas for the clinical use of stem cell transplantation as a potential treatment for IBD.
- 31 July 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (15) , 8494
Open AccessStem Cell-Based Therapies for Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) is a chronic, relapsing disease that severely affects patients’ quality of life. The exact cause of IBD is uncertain, but current studies suggest that abnormal activation of the immune system, genetic susceptibility, and altered intestinal flora due to mucosal barrier defects may play an essential role in the pathogenesis of IBD. Unfortunately, IBD is currently difficult to be wholly cured. Thus, more treatment options are needed for different patients. Stem cell therapy, mainly including hematopoietic stem cell therapy and mesenchymal stem cell therapy, has shown the potential to improve the clinical disease activity of patients when conventional treatments are not effective. Stem cell therapy, an emerging therapy for IBD, can alleviate mucosal inflammation through mechanisms such as immunomodulation and colonization repair. Clinical studies have confirmed the effectiveness of stem cell transplantation in refractory IBD and the ability to maintain long-term remission in some patients. However, stem cell therapy is still in the research stage, and its safety and long-term efficacy remain to be further evaluated. This article reviews the upcoming stem cell transplantation methods for clinical application and the results of ongoing clinical trials to provide ideas for the clinical use of stem cell transplantation as a potential treatment for IBD.